Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Neogen Chemicals Limited (NEOGEN.NS)
Thane, IN
Neogen Chemicals Limited, founded in Thane, India, in 1989, is engaged in the manufacturing and supply of an extensive array of specialized chemical products. The company's comprehensive portfolio encompasses numerous organo-bromine compounds, including alkyl bromides, dibromoalkanes, bromo chloro alkanes, various bromine derivatives (of organoacids, esters, aromatics, and cyclics), and specialty bromo-fluoro derivatives. Additionally, Neogen offers specialty chloro compounds, unsaturated and bromo-hydroxy derivatives, inorganic bromine compounds, lithium salts, Grignard reagents, and advanced intermediates. Beyond its product range, the firm also provides custom synthesis and contract manufacturing services. Neogen's offerings cater to diverse industrial sectors such as pharmaceuticals, agrochemicals, engineering, flavors and fragrances, electronic chemicals, refrigeration, construction, specialty polymers, and heating, ventilation, and air conditioning (HVAC). The company maintains an international presence, exporting its chemicals to 28 nations globally.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.56% | -8.40% | +4.53% | +17.45% | +21.71% | +33.43% | +3.05% | +0.60% | +77.15% | +499.54% | +499.54% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 5 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+10.9% ★ Q1'26: +21.6% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%-17.4% Q1'26: +374.7% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%-38.8% Q1'26: -169.1% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+12.7% ★ Q1'26: +14.7% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+3.5% Q1'26: +4.7% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%0.0% Q1'26: -0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×10.16× Q1'26: 7.94× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 7 Rev. Ana. 6 EPS Ana. |
Mar 2027 7 Rev. Ana. 6 EPS Ana. |
Mar 2028 7 Rev. Ana. 6 EPS Ana. |
Mar 2029 2 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. |
Mar 2031 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.06B
est: 3.06B (+0.0%)
|
3.36B
est: 3.35B (+0.5%)
|
4.87B
est: 4.83B (+1.0%)
|
6.86B
est: 6.86B (+0.0%)
|
6.91B
est: 7.06B (-2.1%)
|
7.78B
est: 8.22B (-5.4%)
|
8.49B
8.35B – 8.59B
+3.2% YoY
|
13.10B
11.32B – 14.12B
+54.4% YoY
|
22.27B
19.88B – 23.24B
+70.0% YoY
|
26.55B
25.65B – 27.44B
+19.2% YoY
|
31.38B
27.67B – 33.16B
+18.2% YoY
|
37.79B
33.33B – 39.93B
+20.4% YoY
|
| EBITDA |
572.95M
est: 537.55M (+6.6%)
|
644.96M
est: 387.83M (+66.3%)
|
865.60M
est: 477.85M (+81.1%)
|
1.16B
est: 570.87M (+103.3%)
|
1.13B
est: 1.24B (-8.5%)
|
1.36B
est: 1.44B (-5.6%)
|
1.49B
1.47B – 1.51B
+3.2% YoY
|
2.30B
1.99B – 2.48B
+54.4% YoY
|
3.91B
3.49B – 4.08B
+70.0% YoY
|
4.66B
4.51B – 4.82B
+19.2% YoY
|
5.51B
4.86B – 5.82B
+18.2% YoY
|
6.64B
5.85B – 7.01B
+20.4% YoY
|
| EBIT |
520.54M
est: 453.69M (+14.7%)
|
575.95M
est: 593.24M (-2.9%)
|
748.70M
est: 730.93M (+2.4%)
|
999.70M
est: 873.21M (+14.5%)
|
905.50M
est: 1.05B (-13.4%)
|
1.09B
est: 1.22B (-10.9%)
|
1.26B
1.24B – 1.27B
+3.2% YoY
|
1.94B
1.68B – 2.09B
+54.4% YoY
|
3.30B
2.95B – 3.44B
+70.0% YoY
|
3.94B
3.80B – 4.07B
+19.2% YoY
|
4.65B
4.10B – 4.91B
+18.2% YoY
|
5.60B
4.94B – 5.92B
+20.4% YoY
|
| Net Income |
286.57M
est: 324.55M (-11.7%)
|
313.30M
est: 321.91M (-2.7%)
|
446.30M
est: 396.62M (+12.5%)
|
499.70M
est: 486.20M (+2.8%)
|
356.50M
est: 373.70M (-4.6%)
|
348.30M
est: 526.19M (-33.8%)
|
287.50M
221.00M – 401.28M
-45.4% YoY
|
578.00M
467.89M – 723.13M
+101.0% YoY
|
1.27B
624.63M – 1.41B
+119.1% YoY
|
1.93B
1.79B – 2.26B
+52.4% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
128.40M
est: 171.73M (-25.2%)
|
125.53M
est: 334.82M (-62.5%)
|
209.00M
est: 412.53M (-49.3%)
|
499.60M
est: 492.84M (+1.4%)
|
304.60M
est: 395.93M (-23.1%)
|
648.40M
est: 461.16M (+40.6%)
|
476.03M
468.51M – 482.06M
+3.2% YoY
|
734.89M
635.27M – 792.02M
+54.4% YoY
|
1.25B
1.12B – 1.30B
+70.0% YoY
|
1.49B
1.44B – 1.54B
+19.2% YoY
|
1.76B
1.55B – 1.86B
+18.2% YoY
|
2.12B
1.87B – 2.24B
+20.4% YoY
|
| EPS |
12.28
est: 12.30 (-0.2%)
|
13.43
est: 16.00 (-16.1%)
|
17.90
est: 18.70 (-4.3%)
|
20.04
est: 20.30 (-1.3%)
|
13.96
est: 14.42 (-3.2%)
|
13.20
est: 20.78 (-36.5%)
|
11.00
8.38 – 15.21
-47.1% YoY
|
21.61
17.73 – 27.41
+96.4% YoY
|
42.40
23.67 – 53.31
+96.2% YoY
|
79.95
67.66 – 85.83
+88.6% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.03% | 238.6K | 0.65% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Harin Haridas Kanani | MD & Executive Director | 15M | — |
| Shyamsunder Radeshyam Upadhyay | Director of Operations & Whole Time Director | 13M | male |
| Unnati Rajesh Kanani | Company Secretary & Compliance Officer | 690.6K | female |
| Pant | Senior Vice President of Business Development | — | — |
| Navin Jha | Senior General Manager of Marketing | — | — |
| Kirit Chauhan | Senior Vice President of Human Resource | — | male |
| Gopikrishnan Sarathy | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NEOGEN.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
